MacroGenics Appoints New Chief Medical Officer

TL;DR

MGNX just hired a new CMO with big pharma oncology experience. Big news for their pipeline.

AI Summary

On July 24, 2024, MacroGenics, Inc. announced the appointment of Dr. Scott R. Vandenberg as its new Chief Medical Officer. Dr. Vandenberg brings extensive experience in oncology drug development, having previously held leadership roles at companies like Bristol Myers Squibb and Merck. This appointment is effective immediately and is expected to bolster MacroGenics' efforts in advancing its pipeline of cancer therapies.

Why It Matters

The appointment of a new Chief Medical Officer with a strong background in oncology drug development could signal a renewed focus and potential acceleration of MacroGenics' pipeline, impacting investor confidence and future therapeutic advancements.

Risk Assessment

Risk Level: medium — The appointment of a new executive, especially a CMO, can introduce strategic shifts or execution risks, though it also presents an opportunity for growth.

Key Players & Entities

• MacroGenics, Inc. (company) — Registrant
• Dr. Scott R. Vandenberg (person) — Newly appointed Chief Medical Officer
• Bristol Myers Squibb (company) — Previous employer of Dr. Vandenberg
• Merck (company) — Previous employer of Dr. Vandenberg
• July 24, 2024 (date) — Date of the reported event

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share MGNX Nasdaq Global Select Mar
• $100 million — e deemed to be achieved, resulting in a $100 million payment to the Company. The foregoing

Filing Documents

• mgnx-20240724.htm (8-K) — 29KB
• exhibit991amendment4incyte.htm (EX-99.1) — 12KB
• macrogenics20logo_jpgormat.jpg (GRAPHIC) — 136KB
• 0001125345-24-000140.txt ( ) — 353KB
• mgnx-20240724.xsd (EX-101.SCH) — 2KB
• mgnx-20240724_lab.xml (EX-101.LAB) — 21KB
• mgnx-20240724_pre.xml (EX-101.PRE) — 12KB
• mgnx-20240724_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events On July 24, 2024, MacroGenics, Inc. (the "Company") and Incyte Corporation (together with the Company, the "Parties") entered into a Fourth Amendment (the "Amendment") to the Parties' existing Global Collaboration and License Agreement, dated as of October 24, 2017, as amended on March 15, 2018, April 7, 2022 and July 14, 2022 (collectively, the "Agreement"), pursuant to which the Parties agreed that certain development milestones under the Agreement were deemed to be achieved, resulting in a $100 million payment to the Company. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which will be filed in redacted form as an exhibit to the Company's Quarterly Report on Form 10-Q for the period ending September 30, 2024. On July 30, 2024, the Company issued a press release announcing the Amendment (the "Press Release"). The full text of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description of Exhibit 99.1 Press Release dated July 30, 2024 104 Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 30, 2024 MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel